Leerink Partners on Viridian Therapeutic (VRDN): share weakness on AMGN results 'overdone'
April 6, 2026 1:12 PM
Leerink Partners analyst Thomas Smith reiterated an Outperform rating and $50.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
